Iantrek

Iantrek, Inc. is an innovative ophthalmic medical technology company founded in 2019 by Dr. Sean Ianchulev, MD, MPH. Based in White Plains, New York, with R&D offices in Providence, Rhode Island, Iantrek focuses on developing micro-interventional and bio-interventional solutions for chronic eye diseases, particularly glaucoma. The company is unique in offering FDA-registered technologies that target both trabecular and suprachoroidal outflow pathways. Iantrek's product portfolio includes the AlloFlo™ Uveo, a bio-tissue implant for enhancing uveoscleral outflow, and the C-Rex™ Device for trabecular meshwork excision. The company is also advancing other solutions like the AlloSert™ Uveo and the CycloPen™ System. Iantrek aims to empower surgeons with tools that improve outcomes in glaucoma care, supported by significant venture funding for its commercial launch and product development. The company has demonstrated strong clinical performance, with notable endorsements from leading experts in the field.